Translated data: C2i Genomics has partnered with Tel Aviv's Sourasky Medical Center to utilize cloud-based AI solutions for early cancer detection. C2i Genomics specializes in whole genome minimal residual disease (MRD) detection, and this collaboration will drive research and clinical trials within the hospital, as well as facilitate drug development for pharmaceutical companies.